JP2014159427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014159427A5 JP2014159427A5 JP2014045733A JP2014045733A JP2014159427A5 JP 2014159427 A5 JP2014159427 A5 JP 2014159427A5 JP 2014045733 A JP2014045733 A JP 2014045733A JP 2014045733 A JP2014045733 A JP 2014045733A JP 2014159427 A5 JP2014159427 A5 JP 2014159427A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ion
- dihydropyridin
- piperazine
- carboxylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 75
- -1 2,3-difluorophenyl Chemical group 0.000 claims 50
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 21
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 21
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 12
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 12
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 claims 12
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 9
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 9
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 9
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 6
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 229940006460 bromide ion Drugs 0.000 claims 3
- 150000007942 carboxylates Chemical class 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 3
- 229940006461 iodide ion Drugs 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 229940085991 phosphate ion Drugs 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- 239000011975 tartaric acid Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 0 *C*(C=CC(C*(CC1)CCN1C(O*)=O)=C1O)C1=O Chemical compound *C*(C=CC(C*(CC1)CCN1C(O*)=O)=C1O)C1=O 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25891409P | 2009-11-06 | 2009-11-06 | |
| US25891809P | 2009-11-06 | 2009-11-06 | |
| US61/258,914 | 2009-11-06 | ||
| US61/258,918 | 2009-11-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537236A Division JP5627040B2 (ja) | 2009-11-06 | 2010-11-05 | 低酸素誘導因子−１αの安定化を増大させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014159427A JP2014159427A (ja) | 2014-09-04 |
| JP2014159427A5 true JP2014159427A5 (enExample) | 2014-10-16 |
| JP5865411B2 JP5865411B2 (ja) | 2016-02-17 |
Family
ID=43970365
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537236A Expired - Fee Related JP5627040B2 (ja) | 2009-11-06 | 2010-11-05 | 低酸素誘導因子−１αの安定化を増大させるための方法 |
| JP2012537240A Expired - Fee Related JP5591939B2 (ja) | 2009-11-06 | 2010-11-05 | 大腸炎を治療するための組成物および方法 |
| JP2012537237A Expired - Fee Related JP5599467B2 (ja) | 2009-11-06 | 2010-11-05 | プロリルヒドロキシラーゼ阻害剤 |
| JP2014045733A Expired - Fee Related JP5865411B2 (ja) | 2009-11-06 | 2014-03-07 | 低酸素誘導因子−１αの安定化を増大させるための方法 |
| JP2014045734A Withdrawn JP2014139206A (ja) | 2009-11-06 | 2014-03-07 | プロリルヒドロキシラーゼ阻害剤 |
| JP2014155145A Expired - Fee Related JP5961665B2 (ja) | 2009-11-06 | 2014-07-30 | 大腸炎を治療するための組成物および方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537236A Expired - Fee Related JP5627040B2 (ja) | 2009-11-06 | 2010-11-05 | 低酸素誘導因子−１αの安定化を増大させるための方法 |
| JP2012537240A Expired - Fee Related JP5591939B2 (ja) | 2009-11-06 | 2010-11-05 | 大腸炎を治療するための組成物および方法 |
| JP2012537237A Expired - Fee Related JP5599467B2 (ja) | 2009-11-06 | 2010-11-05 | プロリルヒドロキシラーゼ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014045734A Withdrawn JP2014139206A (ja) | 2009-11-06 | 2014-03-07 | プロリルヒドロキシラーゼ阻害剤 |
| JP2014155145A Expired - Fee Related JP5961665B2 (ja) | 2009-11-06 | 2014-07-30 | 大腸炎を治療するための組成物および方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (11) | US8536181B2 (enExample) |
| EP (9) | EP2496084B1 (enExample) |
| JP (6) | JP5627040B2 (enExample) |
| KR (8) | KR20140122283A (enExample) |
| CN (3) | CN102595896B (enExample) |
| AU (3) | AU2010314982B2 (enExample) |
| BR (3) | BR112012010766A2 (enExample) |
| CA (3) | CA2774043C (enExample) |
| DK (4) | DK2649998T3 (enExample) |
| ES (5) | ES2644998T3 (enExample) |
| HK (1) | HK1208806A1 (enExample) |
| HR (3) | HRP20130691T1 (enExample) |
| HU (1) | HUE026109T2 (enExample) |
| IL (4) | IL219612A (enExample) |
| IN (3) | IN2012DN04949A (enExample) |
| MX (4) | MX365138B (enExample) |
| MY (3) | MY160066A (enExample) |
| NO (1) | NO2853265T3 (enExample) |
| NZ (4) | NZ600396A (enExample) |
| PH (3) | PH12012500788A1 (enExample) |
| PL (4) | PL2496236T4 (enExample) |
| PT (4) | PT2496084E (enExample) |
| RS (3) | RS52870B (enExample) |
| RU (3) | RU2518416C2 (enExample) |
| SI (2) | SI2649998T1 (enExample) |
| SM (1) | SMT201300096B (enExample) |
| WO (3) | WO2011057121A1 (enExample) |
| ZA (1) | ZA201204104B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| CA2748765C (en) | 2009-07-06 | 2014-07-22 | Akebia Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| WO2011044492A1 (en) * | 2009-10-09 | 2011-04-14 | University Of Rochester | Methods of treatment and screening assays for hif-1alpha regulation |
| ES2644998T3 (es) * | 2009-11-06 | 2017-12-01 | Aerpio Therapeutics Inc. | Métodos para aumentar la estabilización del factor-1 alfa inducible por hipoxia |
| WO2012170442A1 (en) * | 2011-06-06 | 2012-12-13 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| EP3935944A1 (en) * | 2013-03-15 | 2022-01-12 | University Of Southern California, USC Stevens | Compounds for the treatment of musculoskeletal diseases |
| GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| NZ714963A (en) | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| ES2739625T3 (es) * | 2014-02-19 | 2020-02-03 | Aerpio Therapeutics Inc | Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用 |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| WO2019100053A1 (en) | 2017-11-20 | 2019-05-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods for modulating hif-2α to improve muscle generation and repair |
| AU2019265629B2 (en) | 2018-05-09 | 2024-09-12 | Akebia Therapeutics, Inc. | Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| CA3159601A1 (en) * | 2019-11-20 | 2021-05-27 | Angion Biomedica Corp. | Methods for treating inflammatory bowel disease |
| WO2021119033A1 (en) * | 2019-12-09 | 2021-06-17 | Gb004, Inc. | Compositions and methods of treatment |
| AU2021233433A1 (en) * | 2020-03-11 | 2022-10-06 | Kissei Pharmaceutical Co., Ltd. | Crystal of imidazopyridinone compound or salt thereof |
| WO2022036269A1 (en) * | 2020-08-13 | 2022-02-17 | Gb004, Inc. | CRYSTALLINE FORMS OF AN HIF-1α PROLYL HYDROXYLASE INHIBITOR |
| WO2022036267A1 (en) * | 2020-08-13 | 2022-02-17 | Gb004, Inc. | Compositions and methods of treatment |
| CA3206501A1 (en) * | 2021-02-02 | 2022-08-11 | Shaun Abbott | Gpr84 antagonists and uses thereof |
| CA3206499A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| KR102507532B1 (ko) * | 2022-09-14 | 2023-03-10 | 주식회사 에이치디에스바이오 | 락토바실러스 플란타룸 hac03 균주 및 플라보노이드를 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| EP4661861A1 (en) * | 2023-02-06 | 2025-12-17 | Institut National de la Santé et de la Recherche Médicale | Use of hif-1a stabilizing agents for the treatment of type i interferonopathies |
| CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US3894920A (en) * | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US3853900A (en) * | 1973-09-14 | 1974-12-10 | Searle & Co | 4-benzyloxy-2 (1h)-pyridones |
| US5358949A (en) * | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
| TW219933B (enExample) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
| DE4316077A1 (de) * | 1993-05-13 | 1994-11-17 | Bayer Ag | Substituierte Mono- und Bihydridylmethylpyridone |
| ES2101420T3 (es) * | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| US5849587A (en) * | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
| WO1997041103A1 (de) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| UA66370C2 (en) * | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| CN100575345C (zh) | 2000-12-28 | 2009-12-30 | 盐野义制药株式会社 | 对2型大麻素受体具有结合活性的吡啶酮衍生物 |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US20040146964A1 (en) | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
| US6566088B1 (en) * | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| ES2414706T3 (es) | 2001-12-06 | 2013-07-22 | Fibrogen, Inc. | Métodos para aumentar la eritropoyetina endógena |
| ES2248733T3 (es) | 2002-01-11 | 2006-03-16 | Rhodianyl | Utilizacion de sulfuro de zinc como agente anti-acaros. |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| MXPA05004033A (es) | 2002-10-16 | 2005-06-08 | Isis Innovation | Hidroxilasas de asparaginil y moduladores de las mismas. |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| JP4736043B2 (ja) * | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| BRPI0414014A (pt) | 2003-08-26 | 2006-10-24 | Becton Dickinson Co | métodos para distribuição intradérmica de agentes terapêuticos |
| AU2004285351A1 (en) * | 2003-10-31 | 2005-05-12 | Earth Chemical Co., Ltd. | Material in gel state |
| WO2005051933A1 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby |
| JP2007519735A (ja) * | 2004-01-30 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤として有用であるｎ−ベンジル−３，４−ジヒドロキシピリジン−２−カルボキサミド及びｎ−ベンジル−２，３−ジヒドロキシピリジン−４−カルボキサミド化合物 |
| US20050258126A1 (en) | 2004-05-21 | 2005-11-24 | Aniceto Canamasas Puigbo | Double bottomed jar |
| ATE443775T1 (de) | 2004-05-28 | 2009-10-15 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
| US7718624B2 (en) * | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
| WO2006084210A2 (en) | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
| US7588824B2 (en) * | 2005-02-25 | 2009-09-15 | The Regents Of The University Of California | Hydrogen cyano fullerene containing proton conducting membranes |
| JP2008534630A (ja) | 2005-04-08 | 2008-08-28 | ニューロメッド ファーマシューティカルズ リミテッド | 疼痛の軽減のためのｎ型カルシウムチャネルブロッカーを含む組み合わせ治療の方法 |
| US8177417B2 (en) * | 2005-04-25 | 2012-05-15 | Harsco Technologies Corporation | Apparatus for continuous blending |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| EP1893186A2 (en) * | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
| WO2007033216A2 (en) * | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| US7588924B2 (en) * | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| US8968702B2 (en) | 2006-03-30 | 2015-03-03 | Duke University | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses |
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US20090176825A1 (en) | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| BRPI0713350B1 (pt) * | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| JP5265381B2 (ja) | 2006-12-07 | 2013-08-14 | テルモ株式会社 | 輸液チューブセット |
| US7635715B2 (en) | 2006-12-18 | 2009-12-22 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| CA2683758A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| WO2008130508A1 (en) | 2007-04-18 | 2008-10-30 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| WO2008137060A1 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| US8309544B2 (en) | 2007-05-16 | 2012-11-13 | Merck Sharp & Dohme Corp. | Spiroindalones |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| FR2924205B1 (fr) | 2007-11-23 | 2013-08-16 | Air Liquide | Dispositif et procede de refrigeration cryogenique |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| EP2227770A4 (en) | 2007-11-30 | 2011-11-09 | Glaxosmithkline Llc | PROLYLHYDROXYLASEINHIBITOREN |
| US20100305154A1 (en) | 2007-11-30 | 2010-12-02 | Glaxosmithkline Llc | Prolyl Hydroxylase Inhibitors |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| CN102119218A (zh) | 2007-12-13 | 2011-07-06 | 阿彻-丹尼尔斯-米德兰德公司 | 耐热酵母多形汉逊酵母在高温的产乙醇的木糖发酵 |
| WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| WO2009089547A1 (en) | 2008-01-11 | 2009-07-16 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| CN108635350A (zh) | 2009-01-12 | 2018-10-12 | 爱尔皮奥治疗有限公司 | 治疗血管渗漏综合征的方法 |
| CA2748765C (en) | 2009-07-06 | 2014-07-22 | Akebia Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| ES2644998T3 (es) | 2009-11-06 | 2017-12-01 | Aerpio Therapeutics Inc. | Métodos para aumentar la estabilización del factor-1 alfa inducible por hipoxia |
| PH12013500577B1 (en) | 2010-10-07 | 2019-06-28 | Aerpio Therapeutics Inc | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| WO2012170442A1 (en) | 2011-06-06 | 2012-12-13 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| HK1201196A1 (en) | 2011-10-13 | 2015-08-28 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| ES2739625T3 (es) | 2014-02-19 | 2020-02-03 | Aerpio Therapeutics Inc | Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas |
| US9775608B2 (en) | 2014-02-24 | 2017-10-03 | Ethicon Llc | Fastening system comprising a firing member lockout |
-
2010
- 2010-11-05 ES ES14193060.2T patent/ES2644998T3/es active Active
- 2010-11-05 CA CA2774043A patent/CA2774043C/en not_active Expired - Fee Related
- 2010-11-05 PT PT108291808T patent/PT2496084E/pt unknown
- 2010-11-05 CN CN201080050210.1A patent/CN102595896B/zh not_active Expired - Fee Related
- 2010-11-05 AU AU2010314982A patent/AU2010314982B2/en not_active Ceased
- 2010-11-05 RU RU2012123388/15A patent/RU2518416C2/ru not_active IP Right Cessation
- 2010-11-05 NZ NZ600396A patent/NZ600396A/en not_active IP Right Cessation
- 2010-11-05 EP EP10829180.8A patent/EP2496084B1/en active Active
- 2010-11-05 HR HRP20130691AT patent/HRP20130691T1/hr unknown
- 2010-11-05 PL PL10829176T patent/PL2496236T4/pl unknown
- 2010-11-05 BR BR112012010766A patent/BR112012010766A2/pt not_active Application Discontinuation
- 2010-11-05 MY MYPI2012001216A patent/MY160066A/en unknown
- 2010-11-05 AU AU2010314976A patent/AU2010314976B2/en not_active Ceased
- 2010-11-05 WO PCT/US2010/055704 patent/WO2011057121A1/en not_active Ceased
- 2010-11-05 MX MX2013009454A patent/MX365138B/es unknown
- 2010-11-05 PT PT131657496T patent/PT2649998E/pt unknown
- 2010-11-05 KR KR1020147026829A patent/KR20140122283A/ko not_active Withdrawn
- 2010-11-05 EP EP15154363.4A patent/EP2952192B1/en not_active Not-in-force
- 2010-11-05 BR BR112012010762-3A patent/BR112012010762B1/pt not_active IP Right Cessation
- 2010-11-05 EP EP10829174.1A patent/EP2496082B1/en not_active Not-in-force
- 2010-11-05 KR KR1020127014454A patent/KR101483831B1/ko not_active Expired - Fee Related
- 2010-11-05 MY MYPI2012001217A patent/MY163511A/en unknown
- 2010-11-05 DK DK13165749.6T patent/DK2649998T3/en active
- 2010-11-05 US US12/940,891 patent/US8536181B2/en not_active Expired - Fee Related
- 2010-11-05 IN IN4949DEN2012 patent/IN2012DN04949A/en unknown
- 2010-11-05 MX MX2012005274A patent/MX2012005274A/es active IP Right Grant
- 2010-11-05 ES ES15164257T patent/ES2782999T3/es active Active
- 2010-11-05 CA CA2774039A patent/CA2774039A1/en not_active Abandoned
- 2010-11-05 KR KR1020157026346A patent/KR101591701B1/ko not_active Expired - Fee Related
- 2010-11-05 IN IN4950DEN2012 patent/IN2012DN04950A/en unknown
- 2010-11-05 DK DK10829180.8T patent/DK2496084T3/en active
- 2010-11-05 US US12/940,901 patent/US8309537B2/en not_active Expired - Fee Related
- 2010-11-05 NZ NZ600400A patent/NZ600400A/en not_active IP Right Cessation
- 2010-11-05 CN CN201080050212.0A patent/CN102638983B/zh not_active Expired - Fee Related
- 2010-11-05 MX MX2012005275A patent/MX2012005275A/es active IP Right Grant
- 2010-11-05 RU RU2012123387/04A patent/RU2518071C2/ru not_active IP Right Cessation
- 2010-11-05 WO PCT/US2010/055694 patent/WO2011057115A1/en not_active Ceased
- 2010-11-05 NZ NZ600405A patent/NZ600405A/en not_active IP Right Cessation
- 2010-11-05 ES ES13165749.6T patent/ES2533128T3/es active Active
- 2010-11-05 RS RS20130321A patent/RS52870B/sr unknown
- 2010-11-05 US US12/940,883 patent/US8778412B2/en active Active
- 2010-11-05 PT PT141930602T patent/PT2853265T/pt unknown
- 2010-11-05 MX MX2012005273A patent/MX2012005273A/es not_active Application Discontinuation
- 2010-11-05 JP JP2012537236A patent/JP5627040B2/ja not_active Expired - Fee Related
- 2010-11-05 PH PH1/2012/500788A patent/PH12012500788A1/en unknown
- 2010-11-05 EP EP10829176.6A patent/EP2496236B1/en active Active
- 2010-11-05 PT PT108291766T patent/PT2496236E/pt unknown
- 2010-11-05 KR KR1020147017414A patent/KR20140095105A/ko not_active Abandoned
- 2010-11-05 PL PL13165749T patent/PL2649998T3/pl unknown
- 2010-11-05 HR HRP20150772TT patent/HRP20150772T1/hr unknown
- 2010-11-05 PH PH1/2012/500789A patent/PH12012500789A1/en unknown
- 2010-11-05 ES ES10829176T patent/ES2424122T3/es active Active
- 2010-11-05 EP EP14193060.2A patent/EP2853265B1/en not_active Not-in-force
- 2010-11-05 CA CA2774046A patent/CA2774046C/en not_active Expired - Fee Related
- 2010-11-05 EP EP19174520.7A patent/EP3603644A1/en not_active Withdrawn
- 2010-11-05 EP EP13165749.6A patent/EP2649998B1/en not_active Not-in-force
- 2010-11-05 KR KR1020157001507A patent/KR101613103B1/ko not_active Expired - Fee Related
- 2010-11-05 KR KR1020127014419A patent/KR101445946B1/ko not_active Expired - Fee Related
- 2010-11-05 PL PL14193060T patent/PL2853265T3/pl unknown
- 2010-11-05 DK DK10829176.6T patent/DK2496236T3/da active
- 2010-11-05 EP EP15164257.6A patent/EP2954899B1/en active Active
- 2010-11-05 NZ NZ629733A patent/NZ629733A/en not_active IP Right Cessation
- 2010-11-05 ES ES10829180.8T patent/ES2541613T3/es active Active
- 2010-11-05 RS RS20150485A patent/RS54124B1/sr unknown
- 2010-11-05 PH PH1/2012/500790A patent/PH12012500790A1/en unknown
- 2010-11-05 DK DK14193060.2T patent/DK2853265T3/da active
- 2010-11-05 MY MYPI2012001219A patent/MY161880A/en unknown
- 2010-11-05 JP JP2012537240A patent/JP5591939B2/ja not_active Expired - Fee Related
- 2010-11-05 JP JP2012537237A patent/JP5599467B2/ja not_active Expired - Fee Related
- 2010-11-05 BR BR112012010759-3A patent/BR112012010759B1/pt not_active IP Right Cessation
- 2010-11-05 RS RS20150173A patent/RS54010B1/sr unknown
- 2010-11-05 PL PL10829180T patent/PL2496084T3/pl unknown
- 2010-11-05 RU RU2012123386/15A patent/RU2521251C2/ru not_active IP Right Cessation
- 2010-11-05 CN CN201080050181.9A patent/CN102612367B/zh not_active Expired - Fee Related
- 2010-11-05 KR KR1020127014522A patent/KR20120088833A/ko not_active Ceased
- 2010-11-05 SI SI201030927T patent/SI2649998T1/sl unknown
- 2010-11-05 WO PCT/US2010/055691 patent/WO2011057112A1/en not_active Ceased
- 2010-11-05 KR KR1020147008577A patent/KR20140048341A/ko not_active Ceased
- 2010-11-05 HU HUE10829180A patent/HUE026109T2/en unknown
- 2010-11-05 IN IN4940DEN2012 patent/IN2012DN04940A/en unknown
- 2010-11-05 SI SI201030987T patent/SI2496084T1/sl unknown
- 2010-11-05 AU AU2010314973A patent/AU2010314973B9/en not_active Ceased
- 2010-11-05 EP EP20150482.6A patent/EP3698794A1/en not_active Withdrawn
- 2010-11-05 NO NO14193060A patent/NO2853265T3/no unknown
-
2012
- 2012-05-06 IL IL219612A patent/IL219612A/en active IP Right Grant
- 2012-05-06 IL IL219610A patent/IL219610A/en active IP Right Grant
- 2012-05-06 IL IL219611A patent/IL219611A/en not_active IP Right Cessation
- 2012-06-05 ZA ZA2012/04104A patent/ZA201204104B/en unknown
-
2013
- 2013-02-15 US US13/768,308 patent/US9045495B2/en not_active Expired - Fee Related
- 2013-02-19 US US13/770,135 patent/US8883774B2/en active Active
- 2013-09-05 SM SM201300096T patent/SMT201300096B/xx unknown
-
2014
- 2014-03-07 JP JP2014045733A patent/JP5865411B2/ja not_active Expired - Fee Related
- 2014-03-07 JP JP2014045734A patent/JP2014139206A/ja not_active Withdrawn
- 2014-07-30 JP JP2014155145A patent/JP5961665B2/ja not_active Expired - Fee Related
- 2014-08-21 US US14/465,027 patent/US8999971B2/en not_active Expired - Fee Related
-
2015
- 2015-02-22 US US14/628,261 patent/US9278930B2/en not_active Expired - Fee Related
- 2015-04-16 US US14/688,216 patent/US9540326B2/en not_active Expired - Fee Related
- 2015-05-04 HR HRP20150473TT patent/HRP20150473T1/hr unknown
- 2015-07-13 IL IL239918A patent/IL239918A0/en unknown
- 2015-09-29 HK HK15109530.1A patent/HK1208806A1/en unknown
-
2016
- 2016-12-01 US US15/366,437 patent/US20170298019A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/900,447 patent/US10562854B2/en not_active Expired - Fee Related
-
2021
- 2021-12-16 US US17/553,578 patent/US20220185778A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014159427A5 (enExample) | ||
| RU2012123387A (ru) | Ингибиторы пролилгидроксилазы | |
| JP2017502963A5 (enExample) | ||
| CY1124622T1 (el) | Μεθοδοι θεραπειας του καρκινου με τη χρηση 3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο- 2,6-διονης | |
| NZ600707A (en) | 4-oxo-1h-quinoline-3-carboxamides as modulators of atp-binding cassette transporters | |
| WO2016097869A4 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| JP2016540742A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP2018140982A5 (enExample) | ||
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| MX389260B (es) | Sales co-formadoras de (2s,3s)-7-fluoro-2-(4-fluorofenil)-3-(1-metil-1h-1,2,4-triazol-5-il)-4-oxo-1,2,3,4-tetrahidroquinolin-5-carboxilato de metilo y sus metodos de preparacion. | |
| RU2013139300A (ru) | Способ получения 4-амино-3-хлор-5-фтор-6-(замещенных)пиколинатов | |
| JP2019529534A5 (enExample) | ||
| EA200601178A1 (ru) | Морфолинилсодержащие бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса | |
| PE20210859A1 (es) | Inhibidores de triazol glicolato oxidasa | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| JP2014520901A5 (enExample) | ||
| JP2014500864A5 (enExample) | ||
| EA201291431A1 (ru) | Состав для укладки волос | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX368891B (es) | Composición de cuidado oral que contiene sales de zinc y carbonato de calcio. | |
| JP2017226652A5 (enExample) | ||
| JP2016516744A5 (enExample) | ||
| MX2024003926A (es) | Terapia de combinacion que utiliza un inhibidor de ptpn11 y un inhibidor de kras g12c. | |
| GB2543084A (en) | Control of corrosion by molten salts |